1. Home
  2. BVS vs DCTH Comparison

BVS vs DCTH Comparison

Compare BVS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BVS
  • DCTH
  • Stock Information
  • Founded
  • BVS 2011
  • DCTH 1988
  • Country
  • BVS United States
  • DCTH United States
  • Employees
  • BVS N/A
  • DCTH N/A
  • Industry
  • BVS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • DCTH Medical/Dental Instruments
  • Sector
  • BVS Health Care
  • DCTH Health Care
  • Exchange
  • BVS Nasdaq
  • DCTH Nasdaq
  • Market Cap
  • BVS 448.8M
  • DCTH 388.3M
  • IPO Year
  • BVS 2021
  • DCTH N/A
  • Fundamental
  • Price
  • BVS $6.67
  • DCTH $11.47
  • Analyst Decision
  • BVS Strong Buy
  • DCTH Strong Buy
  • Analyst Count
  • BVS 4
  • DCTH 4
  • Target Price
  • BVS $13.75
  • DCTH $24.50
  • AVG Volume (30 Days)
  • BVS 291.4K
  • DCTH 726.3K
  • Earning Date
  • BVS 11-04-2025
  • DCTH 11-07-2025
  • Dividend Yield
  • BVS N/A
  • DCTH N/A
  • EPS Growth
  • BVS N/A
  • DCTH N/A
  • EPS
  • BVS 0.03
  • DCTH 0.06
  • Revenue
  • BVS $564,142,000.00
  • DCTH $70,240,000.00
  • Revenue This Year
  • BVS N/A
  • DCTH $159.22
  • Revenue Next Year
  • BVS $6.88
  • DCTH $42.78
  • P/E Ratio
  • BVS $237.41
  • DCTH $202.86
  • Revenue Growth
  • BVS 5.08
  • DCTH 491.35
  • 52 Week Low
  • BVS $5.81
  • DCTH $8.35
  • 52 Week High
  • BVS $14.38
  • DCTH $18.23
  • Technical
  • Relative Strength Index (RSI)
  • BVS 45.07
  • DCTH 56.62
  • Support Level
  • BVS $6.37
  • DCTH $10.47
  • Resistance Level
  • BVS $6.83
  • DCTH $11.26
  • Average True Range (ATR)
  • BVS 0.25
  • DCTH 0.48
  • MACD
  • BVS -0.02
  • DCTH 0.06
  • Stochastic Oscillator
  • BVS 44.63
  • DCTH 65.36

About BVS Bioventus Inc.

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: